Pliant Therapeutics to Present PLN-101095 Trial Data at ESMO Congress
What happened
Pliant Therapeutics announced it will present clinical data at the European Society for Medical Oncology Congress 2026 in Madrid, Spain. The presentation covers FORTIFY, a Phase 1b trial for PLN-101095. This trial is evaluating the safety, tolerability, and preliminary antitumor activity of PLN-101095 when combined with pembrolizumab in patients with ICI-refractory advanced or metastatic solid tumors.
From manilatimes.net
Why it matters
The presentation details the progress of PLN-101095, a drug candidate being tested for solid tumors. Clinical trial updates like this could influence future investment and commercial viability for Pliant Therapeutics.
From manilatimes.net
Who's involved
- European Society for Medical OncologyHosting the congress where Pliant Therapeutics will present its clinical data.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
European Society for Medical Oncology
Professional organisation
-
South San Francisco
city in San Mateo County, California, United States
Nothing else this week.
Related events
- AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- Faron Pharmaceuticals presented clinical data at the ESMO Congress on October 19, 2026.
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.